{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T09:29:12Z","timestamp":1795080552546,"version":"4.10.2"},"reference-count":71,"publisher":"Bentham Science Publishers Ltd.","issue":"6","funder":[{"name":"Shanghai Songjiang District Science and Technology Research Project","award":["2019SJKJGG01"],"award-info":[{"award-number":["2019SJKJGG01"]}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is the second most common hematologic\nmalignancy, accounting for approximately 10% of all hematological cases, with\nhigher morbidity and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study aimed to investigate the clonal evolutionary characteristics to identify\nnovel prognostic biomarkers associated with extramedullary progression in MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We downloaded transcriptomic profiles and single-cell microarray (scRNA-seq)\ndata from public databases. Then, we used the LASSO method to develop a prognostic\nsignature and validated its efficacy using external MM cohorts. We evaluated the differences\nin the immune microenvironment and drug sensitivity (IC50) between the different\nrisk score groups. scRNA-seq analysis identified key cell types through AUCell\nscores, cell communication, and differentiation trajectory analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In total, 126 DEGs were identified as crucial genes associated with extramedullary\nand intramedullary MM. After LASSO analysis, seven signature genes were selected\nto develop a risk score model, and high-risk patients showed worse outcomes. Subsequently,\nthe nomogram incorporating age, albumin, b2m, LDH, and RiskScore predicted\n1-, 3-, and 5-year outcomes with high AUCs. Immune analyses showed that 25 immune\ncell types, 35 immune checkpoints, 27 chemokines, 20 MHC molecules, and 14 receptor-\nrelated genes differed significantly between the two risk groups. We also identified\n116 drugs (roscovitine and JNK inhibitor VIII) with significantly different IC50 values\nbetween the two risk groups. CD4+ T cells exhibited the highest signature gene activity.\nCellChat analysis demonstrated enhanced communication between CD4+, NK, and\nCD8+ T cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our study has proposed a risk score model based on seven identified signature\ngenes for MM prognosis and revealed CD4+ T cells to be a major immune cell type\nassociated with MM progression, contributing to personalized treatment decision-making\nand precise risk stratification of MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0109298673352012250414100227","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T03:05:11Z","timestamp":1746500711000},"page":"1190-1211","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Single-cell RNA Sequencing Identifies Prognostic Biomarkers in Extramedullary Multiple Myeloma"],"prefix":"10.2174","volume":"33","author":[{"given":"Menghan","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Hematology, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Hematology, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","volume":"9","author":"Huang J.","year":"2022","unstructured":"Huang J.; Chan S.C.; Lok V.; Zhang L.; Lucero-Prisno D.E.; Xu W.; Zheng Z.J.; Elcarte E.; Withers M.; Wong M.C.S.; The epidemiological landscape of multiple myeloma: A global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol  2022,9(9),e670-e677","journal-title":"Lancet Haematol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3322\/caac.21771","volume":"73","author":"Parikh R.H.","year":"2023","unstructured":"Parikh R.H.; Lonial S.; Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice. CA Cancer J Clin  2023,73(3),275-285","journal-title":"CA Cancer J Clin"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"Cowan A.J.","year":"2022","unstructured":"Cowan A.J.; Green D.J.; Kwok M.; Lee S.; Coffey D.G.; Holmberg L.A.; Tuazon S.; Gopal A.K.; Libby E.N.; Diagnosis and management of multiple myeloma. JAMA  2022,327(5),464-477","journal-title":"JAMA"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1200\/JCO.19.02515","volume":"38","author":"Joseph N.S.","year":"2020","unstructured":"Joseph N.S.; Kaufman J.L.; Dhodapkar M.V.; Hofmeister C.C.; Almaula D.K.; Heffner L.T.; Gupta V.A.; Boise L.H.; Lonial S.; Nooka A.K.; Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol  2020,38(17),1928-1937","journal-title":"J Clin Oncol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1146\/annurev-med-050522-033815","volume":"75","author":"Garfall A.L.","year":"2024","unstructured":"Garfall A.L.; New biological therapies for multiple myeloma. Annu Rev Med  2024,75(1),13-29","journal-title":"Annu Rev Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1200\/JCO.23.00512","volume":"41","author":"Holstein S.A.","year":"2023","unstructured":"Holstein S.A.; Grant S.J.; Wildes T.M.; Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: Moving into the future. J Clin Oncol  2023,41(27),4416-4429","journal-title":"J Clin Oncol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41408-024-01068-w","volume":"14","author":"Dima D.","year":"2024","unstructured":"Dima D.; Abdallah A.O.; Davis J.A.; Awada H.; Goel U.; Rashid A.; DeJarnette S.; Anwer F.; Shune L.; Raza S.; Mahmoudjafari Z.; Williams L.; Faiman B.; McGuirk J.P.; Sauter C.S.; Ahmed N.; Khouri J.; Hashmi H.; Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy. Blood Cancer J  2024,14(1),90","journal-title":"Blood Cancer J"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"Blad\u00e9 J.","year":"2022","unstructured":"Blad\u00e9 J.; Beksac M.; Caers J.; Jurczyszyn A.; von Lilienfeld-Toal M.; Moreau P.; Rasche L.; Rosi\u00f1ol L.; Usmani S.Z.; Zamagni E.; Richardson P.; Extramedullary disease in multiple myeloma: A systematic literature review. Blood Cancer J  2022,12(3),45","journal-title":"Blood Cancer J"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","volume":"34","author":"Bhutani M.","year":"2020","unstructured":"Bhutani M.; Foureau D.M.; Atrash S.; Voorhees P.M.; Usmani S.Z.; Extramedullary multiple myeloma. Leukemia  2020,34(1),1-20","journal-title":"Leukemia"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1158\/1078-0432.CCR-19-0694","volume":"26","author":"Ryu D.","year":"2020","unstructured":"Ryu D.; Kim S.J.; Hong Y.; Jo A.; Kim N.; Kim H.J.; Lee H.O.; Kim K.; Park W.Y.; Alterations in the transcriptional programs of myeloma cells and the microenvironment during extramedullary progression affect proliferation and immune evasion. Clin Cancer Res  2020,26(4),935-944","journal-title":"Clin Cancer Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1097\/CM9.0000000000002351","volume":"135","author":"Xia Y.","year":"2022","unstructured":"Xia Y.; Shi Y.; Chen Z.; Zhang J.; Zhu Y.; Guo R.; Zhang R.; Shi Q.; Li J.; Chen L.; Characteristics and prognostic value of extramedullary chromosomal abnormalities in extramedullary myeloma. Chin Med J  2022,135(20),2500-2502","journal-title":"Chin Med J"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/s41375-024-02206-w","volume":"38","author":"Jelinek T.","year":"2024","unstructured":"Jelinek T.; Zihala D.; Sevcikova T.; Anilkumar Sithara A.; Kapustova V.; Sahinbegovic H.; Venglar O.; Muronova L.; Broskevicova L.; Nenarokov S.; Bilek D.; Popkova T.; Plonkova H.; Vrana J.; Zidlik V.; Hurnik P.; Havel M.; Hrdinka M.; Chyra Z.; Stracquadanio G.; Simicek M.; Hajek R.; Beyond the marrow: Insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors. Leukemia  2024,38(6),1323-1333","journal-title":"Leukemia"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"Chari A.","year":"2022","unstructured":"Chari A.; Minnema M.C.; Berdeja J.G.; Oriol A.; van de Donk N.W.C.J.; Rodr\u00edguez-Otero P.; Askari E.; Mateos M.V.; Costa L.J.; Caers J.; Verona R.; Girgis S.; Yang S.; Goldsmith R.B.; Yao X.; Pillarisetti K.; Hilder B.W.; Russell J.; Goldberg J.D.; Krishnan A.; Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med  2022,387(24),2232-2244","journal-title":"N Engl J Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41375-021-01343-w","volume":"36","author":"Jelinek T.","year":"2022","unstructured":"Jelinek T.; Sevcikova T.; Zihala D.; Popkova T.; Kapustova V.; Broskevicova L.; Capkova L.; Rihova L.; Bezdekova R.; Sevcikova S.; Zidlik V.; Havel M.; Plonkova H.; Jungova A.; Minarik J.; Stork M.; Pour L.; Pavlicek P.; Spicka I.; Maisnar V.; Radocha J.; Simicek M.; Hajek R.; Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia  2022,36(1),288-291","journal-title":"Leukemia"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"Moreau P.","year":"2022","unstructured":"Moreau P.; Garfall A.L.; van de Donk N.W.C.J.; Nahi H.; San-Miguel J.F.; Oriol A.; Nooka A.K.; Martin T.; Rosinol L.; Chari A.; Karlin L.; Benboubker L.; Mateos M.V.; Bahlis N.; Popat R.; Besemer B.; Mart\u00ednez-L\u00f3pez J.; Sidana S.; Delforge M.; Pei L.; Trancucci D.; Verona R.; Girgis S.; Lin S.X.W.; Olyslager Y.; Jaffe M.; Uhlar C.; Stephenson T.; Van Rampelbergh R.; Banerjee A.; Goldberg J.D.; Kobos R.; Krishnan A.; Usmani S.Z.; Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med  2022,387(6),495-505","journal-title":"N Engl J Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3324\/haematol.2013.087809","volume":"99","author":"L\u00f3pez-Corral L.","year":"2014","unstructured":"L\u00f3pez-Corral L.; Corchete L.A.; Sarasquete M.E.; Mateos M.V.; Garc\u00eda-Sanz R.; Fermi\u00f1\u00e1n E.; Lahuerta J.J.; Blad\u00e9 J.; Oriol A.; Teruel A.I.; Martino M.L.; Hern\u00e1ndez J.; Hern\u00e1ndez-Rivas J.M.; Burguillo F.J.; San Miguel J.F.; Guti\u00e9rrez N.C.; Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. Haematologica  2014,99(8),1365-1372","journal-title":"Haematologica"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"e1003323","DOI":"10.1371\/journal.pmed.1003323","volume":"17","author":"Danziger S.A.","year":"2020","unstructured":"Danziger S.A.; McConnell M.; Gockley J.; Young M.H.; Rosenthal A.; Schmitz F.; Reiss D.J.; Farmer P.; Alapat D.V.; Singh A.; Ashby C.; Bauer M.; Ren Y.; Smith K.; Couto S.S.; van Rhee F.; Davies F.; Zangari M.; Petty N.; Orlowski R.Z.; Dhodapkar M.V.; Copeland W.B.; Fox B.; Hoering A.; Fitch A.; Newhall K.; Barlogie B.; Trotter M.W.B.; Hershberg R.M.; Walker B.A.; Dervan A.P.; Ratushny A.V.; Morgan G.J.; Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the total therapy clinical trials. PLoS Med  2020,17(11),e1003323","journal-title":"PLoS Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"e75340","DOI":"10.7554\/eLife.75340","volume":"11","author":"Zhong L.","year":"2022","unstructured":"Zhong L.; Hao P.; Zhang Q.; Jiang T.; Li H.; Xiao J.; Li C.; Luo L.; Xie C.; Hu J.; Wang L.; Liu Y.; Shi Y.; Zhang W.; Gong B.; Revised international staging system (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma (MM). eLife  2022,11,e75340","journal-title":"eLife"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"Ritchie M.E.","year":"2015","unstructured":"Ritchie M.E.; Phipson B.; Wu D.; Hu Y.; Law C.W.; Shi W.; Smyth G.K.; limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res  2015,43(7),e47","journal-title":"Nucleic Acids Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Gu Z.","year":"2016","unstructured":"Gu Z.; Eils R.; Schlesner M.; Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics  2016,32(18),2847-2849","journal-title":"Bioinformatics"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1471-2105-12-35","volume":"12","author":"Chen H.","year":"2011","unstructured":"Chen H.; Boutros P.C.J.B.b.; VennDiagram: A package for the generation of highly-customizable Venn and Euler diagrams in R. BMC Bioinformatics  2011,12,35","journal-title":"BMC Bioinformatics"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"Yu G.","year":"2012","unstructured":"Yu G.; Wang L.G.; Han Y.; He Q.Y.; clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS  2012,16(5),284-287","journal-title":"OMICS"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1080\/15366367.2019.1565254","volume":"17","author":"Villanueva R.A.M.","year":"2019","unstructured":"Villanueva R.A.M.; Chen Z.J.; ggplot2: Elegant graphics for data analysis. Measurement  2019,17(3),160-167","journal-title":"Measurement"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/jhered\/esac006","volume":"113","author":"Yang L.","year":"2022","unstructured":"Yang L.; Qu Q.; Hao Z.; Sha K.; Li Z.; Li S.; Powerful identification of large quantitative trait loci using genome-wide R\/glmnet-based regression. J Hered  2022,113(4),472-478","journal-title":"J Hered"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12920-023-01590-z","volume":"16","author":"Li C.","year":"2023","unstructured":"Li C.; Zhang Y.; Construction and validation of a cuproptosis-related five-lncRNA signature for predicting prognosis, immune response and drug sensitivity in breast cancer. BMC Med Genomics  2023,16(1),158","journal-title":"BMC Med Genomics"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"707041","DOI":"10.3389\/fonc.2021.707041","volume":"11","author":"Yang H.","year":"2021","unstructured":"Yang H.; Wang K.; Li B.; Li S.; Li Y.; Yuan L.; The prognostic role of blood inflammatory biomarkers and EGFR mutation status in stage IIIA\/N2 non-small cell lung cancer patients treated with trimodality therapy. Front Oncol  2021,11,707041","journal-title":"Front Oncol"},{"key":"ref=27","first-page":"129","author":"Norbert W.","year":"1964","unstructured":"Norbert W.;  In Extrapolation, Interpolation, and Smoothing of Stationary Time Series: With Engineering Applications  1964,129-148","journal-title":"In Extrapolation, Interpolation, and Smoothing of Stationary Time Series: With Engineering Applications"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"Liberzon A.","year":"2011","unstructured":"Liberzon A.; Subramanian A.; Pinchback R.; Thorvaldsd\u00f3ttir H.; Tamayo P.; Mesirov J.P.; Molecular signatures database (MSigDB) 3.0. Bioinformatics  2011,27(12),1739-1740","journal-title":"Bioinformatics"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"Charoentong P.","year":"2017","unstructured":"Charoentong P.; Finotello F.; Angelova M.; Mayer C.; Efremova M.; Rieder D.; Hackl H.; Trajanoski Z.; Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep  2017,18(1),248-262","journal-title":"Cell Rep"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"e10247","DOI":"10.1371\/journal.pone.0010247","volume":"5","author":"Su\u00e1rez-Fari\u00f1as M.","year":"2010","unstructured":"Su\u00e1rez-Fari\u00f1as M.; Lowes M.A.; Zaba L.C.; Krueger J.G.; Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA). PLoS One  2010,5(4),e10247","journal-title":"PLoS One"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"e107468","DOI":"10.1371\/journal.pone.0107468","volume":"9","author":"Geeleher P.","year":"2014","unstructured":"Geeleher P.; Cox N.; Huang R.S.; pRRophetic: An R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One  2014,9(9),e107468","journal-title":"PLoS One"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"e89782","DOI":"10.1371\/journal.pone.0089782","volume":"9","author":"Wang H.","year":"2014","unstructured":"Wang H.; Zhao Y.; Zhang C.; Li M.; Jiang C.; Li Y.; Rab27a was identified as a prognostic biomaker by mRNA profiling, correlated with malignant progression and subtype preference in gliomas. PLoS One  2014,9(2),e89782","journal-title":"PLoS One"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"Jin S.","year":"2021","unstructured":"Jin S.; Guerrero-Juarez C.F.; Zhang L.; Chang I.; Ramos R.; Kuan C.H.; Myung P.; Plikus M.V.; Nie Q.; Inference and analysis of cell-cell communication using CellChat. Nat Commun  2021,12(1),1088","journal-title":"Nat Commun"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nmeth.4150","volume":"14","author":"Qiu X.","year":"2017","unstructured":"Qiu X.; Hill A.; Packer J.; Lin D.; Ma Y.A.; Trapnell C.; Single-cell mRNA quantification and differential analysis with Census. Nat Methods  2017,14(3),309-315","journal-title":"Nat Methods"},{"key":"ref=35","author":"Kassambara A.J.R.p.v.","year":"2018","unstructured":"Kassambara A.J.R.p.v.; ggpubr: \u2018ggplot2\u2019 Based publication ready plots.  Available from:  https:\/\/rpkgs.datanovia.com\/ggpubr\/2018"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","volume":"28","author":"Tay R.E.","year":"2021","unstructured":"Tay R.E.; Richardson E.K.; Toh H.C.; Revisiting the role of CD4 T cells in cancer immunotherapy\u2014new insights into old paradigms. Cancer Gene Ther  2021,28(1-2),5-17","journal-title":"Cancer Gene Ther"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","volume":"18","author":"Borst J.","year":"2018","unstructured":"Borst J.; Ahrends T.; B\u0105ba\u0142a N.; Melief C.J.M.; Kastenm\u00fcller W.; CD4 T cell help in cancer immunology and immunotherapy. Nat Rev Immunol  2018,18(10),635-647","journal-title":"Nat Rev Immunol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1600-065X.2008.00616.x","volume":"222","author":"Kennedy R.","year":"2008","unstructured":"Kennedy R.; Celis E.; Multiple roles for CD4 T cells in anti-tumor immune responses. Immunol Rev  2008,222(1),129-144","journal-title":"Immunol Rev"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1182\/blood-2009-10-246660","volume":"115","author":"Prabhala R.H.","year":"2010","unstructured":"Prabhala R.H.; Pelluru D.; Fulciniti M.; Prabhala H.K.; Nanjappa P.; Song W.; Pai C.; Amin S.; Tai Y.T.; Richardson P.G.; Ghobrial I.M.; Treon S.P.; Daley J.F.; Anderson K.C.; Kutok J.L.; Munshi N.C.; Elevated IL-17 produced by Th17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood  2010,115(26),5385-5392","journal-title":"Blood"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1038\/bcj.2013.34","volume":"3","author":"Bryant C.","year":"2013","unstructured":"Bryant C.; Suen H.; Brown R.; Yang S.; Favaloro J.; Aklilu E.; Gibson J.; Ho P.J.; Iland H.; Fromm P.; Woodland N.; Nassif N.; Hart D.; Joshua D.E.; Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg\/Th17 balance. Blood Cancer J  2013,3(9),e148","journal-title":"Blood Cancer J"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2005-08-3101","volume":"107","author":"Prabhala R.H.","year":"2006","unstructured":"Prabhala R.H.; Neri P.; Bae J.E.; Tassone P.; Shammas M.A.; Allam C.K.; Daley J.F.; Chauhan D.; Blanchard E.; Thatte H.S.; Anderson K.C.; Munshi N.C.; Dysfunctional T regulatory cells in multiple myeloma. Blood  2006,107(1),301-304","journal-title":"Blood"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1365-3083.2010.02463.x","volume":"72","author":"Brimnes M.K.","year":"2010","unstructured":"Brimnes M.K.; Vangsted A.J.; Knudsen L.M.; Gimsing P.; Gang A.O.; Johnsen H.E.; Svane I.M.; Increased level of both CD4FOXP3+ regulatory T cells and CD14+HLA-DR\/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol  2010,72(6),540-547","journal-title":"Scand J Immunol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1182\/blood-2008-06-161281","volume":"113","author":"Spanoudakis E.","year":"2009","unstructured":"Spanoudakis E.; Hu M.; Naresh K.; Terpos E.; Melo V.; Reid A.; Kotsianidis I.; Abdalla S.; Rahemtulla A.; Karadimitris A.; Regulation of multiple myeloma survival and progression by CD1d. Blood  2009,113(11),2498-2507","journal-title":"Blood"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"6035","DOI":"10.1182\/bloodadvances.2023009890","volume":"7","author":"Gudgeon N.","year":"2023","unstructured":"Gudgeon N.; Giles H.; Bishop E.L.; Fulton-Ward T.; Escribano-Gonzalez C.; Munford H.; James-Bott A.; Foster K.; Karim F.; Jayawardana D.; Mahmood A.; Cribbs A.P.; Tennant D.A.; Basu S.; Pratt G.; Dimeloe S.; Uptake of long-chain fatty acids from the bone marrow suppresses CD8 T-cell metabolism and function in multiple myeloma. Blood Adv  2023,7(20),6035-6047","journal-title":"Blood Adv"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s12032-023-02123-5","volume":"40","author":"Jiang Y.","year":"2023","unstructured":"Jiang Y.; Yao J.; Yao Z.; Huang Y.; Li Z.; Fan Z.; Zhou Y.; Li G.; Li Z.; Xu B.; CD4 T cells in chronic myeloid leukemia present MHC class II-dependent and IFN-\u03b3-dependent cytotoxic capacity. Med Oncol  2023,40(9),253","journal-title":"Med Oncol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1182\/bloodadvances.2023012416","volume":"8","author":"Ledergor G.","year":"2024","unstructured":"Ledergor G.; Fan Z.; Wu K.; McCarthy E.; Hyrenius-Wittsten A.; Starzinski A.; Chang H.; Bridge M.; Kwek S.; Cheung A.; Bylsma S.; Hansen E.; Wolf J.; Wong S.; Shah N.; Roybal K.T.; Martin T.; Ye C.J.; Fong L.; CD4 CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy. Blood Adv  2024,8(13),3562-3575","journal-title":"Blood Adv"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s43018-022-00338-5","volume":"3","author":"Cohen M.","year":"2022","unstructured":"Cohen M.; Giladi A.; Barboy O.; Hamon P.; Li B.; Zada M.; Gurevich-Shapiro A.; Beccaria C.G.; David E.; Maier B.B.; Buckup M.; Kamer I.; Deczkowska A.; Le Berichel J.; Bar J.; Iannacone M.; Tanay A.; Merad M.; Amit I.; The interaction of CD4 helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response. Nat Cancer  2022,3(3),303-317","journal-title":"Nat Cancer"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1006\/cimm.1994.1208","volume":"157","author":"Chong A.S.F.","year":"1994","unstructured":"Chong A.S.F.; Boussy I.A.; Jiang X.L.; Lamas M.; Graf L.H.; CD54\/ICAM-1 is a costimulator of NK cell-mediated cytotoxicity. Cell Immunol  1994,157(1),92-105","journal-title":"Cell Immunol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1182\/blood-2010-10-315457","volume":"117","author":"Crozat K.","year":"2011","unstructured":"Crozat K.; Eidenschenk C.; Jaeger B.N.; Krebs P.; Guia S.; Beutler B.; Vivier E.; Ugolini S.; Impact of \u03b22 integrin deficiency on mouse natural killer cell development and function. Blood  2011,117(10),2874-2882","journal-title":"Blood"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.omto.2021.08.015","volume":"23","author":"Wang T.","year":"2021","unstructured":"Wang T.; Ma F.; Qian H.; Defueling the cancer: ATP synthase as an emerging target in cancer therapy. Mol Ther Oncolytics  2021,23,82-95","journal-title":"Mol Ther Oncolytics"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1083\/jcb.201805099","volume":"218","author":"Patr\u00f3n L.A.","year":"2019","unstructured":"Patr\u00f3n L.A.; Nagatomo K.; Eves D.T.; Imad M.; Young K.; Torvund M.; Guo X.; Rogers G.C.; Zinsmaier K.E.; Cul4 ubiquitin ligase cofactor DCAF12 promotes neurotransmitter release and homeostatic plasticity. J Cell Biol  2019,218(3),993-1010","journal-title":"J Cell Biol"},{"key":"ref=52","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317703923","volume":"39","author":"Yang Y.","year":"2017","unstructured":"Yang Y.; Wang S.; Li J.; Qi S.; Zhang D.; CUL4A as a marker and potential therapeutic target in multiple myeloma. Tumour Biol  2017,39(7)","journal-title":"Tumour Biol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.3390\/jcm10122683","volume":"10","author":"Barankiewicz J.","year":"2021","unstructured":"Barankiewicz J.; Szumera-Cie\u0107kiewicz A.; Salomon-Perzy\u0144ski A.; Wieszczy P.; Malenda A.; Garbicz F.; Prochorec-Sobieszek M.; Misiewicz-Krzemi\u0144ska I.; Juszczy\u0144ski P.; Lech-Mara\u0144da E.; The CRBN, CUL4A and DDB1 expression predicts the response to immunomodulatory drugs and survival of multiple myeloma patients. J Clin Med  2021,10(12),2683","journal-title":"J Clin Med"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"e27707","DOI":"10.1371\/journal.pone.0027707","volume":"6","author":"Carvalho F.","year":"2011","unstructured":"Carvalho F.; Costa E.T.; Camargo A.A.; Gregorio J.C.; Masotti C.; Andrade V.C.C.; Strauss B.E.; Caballero O.L.; Atanackovic D.; Colleoni G.W.B.; Targeting MAGE-C1\/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines. PLoS One  2011,6(11),e27707","journal-title":"PLoS One"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00262-012-1376-4","volume":"62","author":"de Carvalho F.","year":"2013","unstructured":"de Carvalho F.; Alves V.L.F.; Braga W.M.T.; Xavier C.V.; Colleoni G.W.B.; MAGE-C1\/CT7 and MAGE-C2\/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy. Cancer Immunol Immunother  2013,62(1),191-195","journal-title":"Cancer Immunol Immunother"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"a028449","DOI":"10.1101\/cshperspect.a028449","volume":"10","author":"Lin J.X.","year":"2018","unstructured":"Lin J.X.; Leonard W.J.; The common cytokine receptor \u03b3 chain family of cytokines. Cold Spring Harb Perspect Biol  2018,10(9),a028449","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4049\/jimmunol.181.1.225","volume":"181","author":"Bayer A.L.","year":"2008","unstructured":"Bayer A.L.; Lee J.Y.; de la Barrera A.; Surh C.D.; Malek T.R.; A function for IL-7R for CD4CD25+Foxp3+ T regulatory cells. J Immunol  2008,181(1),225-234","journal-title":"J Immunol"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.4049\/jimmunol.181.5.3285","volume":"181","author":"Vang K.B.","year":"2008","unstructured":"Vang K.B.; Yang J.; Mahmud S.A.; Burchill M.A.; Vegoe A.L.; Farrar M.A.; IL-2, -7, and -15, but not thymic stromal lymphopoietin, redundantly govern CD4Foxp3+ regulatory T cell development. J Immunol  2008,181(5),3285-3290","journal-title":"J Immunol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.3390\/ijms22073587","volume":"22","author":"B\u0119bnowska D.","year":"2021","unstructured":"B\u0119bnowska D.; Hrynkiewicz R.; Grywalska E.; Pasiarski M.; Sosnowska-Pasiarska B.; Smarz-Widelska I.; G\u00f3\u017ad\u017a S.; Roli\u0144ski J.; Nied\u017awiedzka-Rystwej P.; Immunological prognostic factors in multiple myeloma. Int J Mol Sci  2021,22(7),3587","journal-title":"Int J Mol Sci"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00277-017-3125-4","volume":"96","author":"Wang L.","year":"2017","unstructured":"Wang L.; Wang J.; Liu W.; Wang W.; Wang H.; Chen X.; Geng Q.; Lu Y.; Xia Z.; High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma. Ann Hematol  2017,96(12),2079-2088","journal-title":"Ann Hematol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12943-023-01826-7","volume":"22","author":"Muhammad S.","year":"2023","unstructured":"Muhammad S.; Fan T.; Hai Y.; Gao Y.; He J.; Reigniting hope in cancer treatment: The promise and pitfalls of IL-2 and IL-2R targeting strategies. Mol Cancer  2023,22(1),121","journal-title":"Mol Cancer"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"TPS8068","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8068","volume":"41","author":"Hess D.","year":"2023","unstructured":"Hess D.; Iversen K.F.; Mateos M.-V.; Pabst T.; Rosi\u00f1ol L.; Kovacikova J.; Schnetzler S.J.; OMNIA-2: Phase I\/II study of ANV419, an IL-2R-\u03b2\u03b3 targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma. JCO  2023,41(16_suppl),TPS8068","journal-title":"JCO"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/j.1440-1827.2011.02716.x","volume":"61","author":"Song M.J.","year":"2011","unstructured":"Song M.J.; Jung C.K.; Park C.H.; Hur W.; Choi J.E.; Bae S.H.; Choi J.Y.; Choi S.W.; Han N.I.; Yoon S.K.; RPL36 as a prognostic marker in hepatocellular carcinoma. Pathol Int  2011,61(11),638-644","journal-title":"Pathol Int"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41467-020-20841-6","volume":"12","author":"Cao X.","year":"2021","unstructured":"Cao X.; Khitun A.; Luo Y.; Na Z.; Phoodokmai T.; Sappakhaw K.; Olatunji E.; Uttamapinant C.; Slavoff S.A.; Alt-RPL36 downregulates the PI3K-AKT-mTOR signaling pathway by interacting with TMEM24. Nat Commun  2021,12(1),508","journal-title":"Nat Commun"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.7150\/jca.39671","volume":"11","author":"Wang Z.","year":"2020","unstructured":"Wang Z.; Li J.; Long X.; Jiao L.; Zhou M.; Wu K.; MRPS16 facilitates tumor progression via the PI3K\/AKT\/Snail signaling axis. J Cancer  2020,11(8),2032-2043","journal-title":"J Cancer"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s13046-021-02008-3","volume":"40","author":"Liao Y.","year":"2021","unstructured":"Liao Y.; Shao Z.; Liu Y.; Xia X.; Deng Y.; Yu C.; Sun W.; Kong W.; He X.; Liu F.; Guo Z.; Chen G.; Tang D.; Gan H.; Liu J.; Huang H.; USP1-dependent RPS16 protein stability drives growth and metastasis of human hepatocellular carcinoma cells. J Exp Clin Cancer Res  2021,40(1),201","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1182\/blood-2005-01-0320","volume":"106","author":"Raje N.","year":"2005","unstructured":"Raje N.; Kumar S.; Hideshima T.; Roccaro A.; Ishitsuka K.; Yasui H.; Shiraishi N.; Chauhan D.; Munshi N.C.; Green S.R.; Anderson K.C.; Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood  2005,106(3),1042-1047","journal-title":"Blood"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1158\/0008-5472.CAN-05-0233","volume":"65","author":"MacCallum D.E.","year":"2005","unstructured":"MacCallum D.E.; Melville J.; Frame S.; Watt K.; Anderson S.; Gianella-Borradori A.; Lane D.P.; Green S.R.; Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res  2005,65(12),5399-5407","journal-title":"Cancer Res"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"8797","DOI":"10.1038\/sj.onc.1206919","volume":"22","author":"Hideshima T.","year":"2003","unstructured":"Hideshima T.; Hayashi T.; Chauhan D.; Akiyama M.; Richardson P.; Anderson K.; Biologic sequelae of c-Jun NH2-terminal kinase (JNK) activation in multiple myeloma cell lines. Oncogene  2003,22(54),8797-8801","journal-title":"Oncogene"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1182\/blood.V108.11.3411.3411","volume":"108","author":"Colla S.","year":"2006","unstructured":"Colla S.; Zhan F.; Yaccoby S.; Epstein J.; Barlogie B.; Shaughnessy J.D.; Regulates J.N.K.; JNK regulates DKK1 expression in multiple myeloma cells. Blood  2006,108(11),3411-3411","journal-title":"Blood"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1186\/s12885-022-09775-y","volume":"22","author":"Salimi A.","year":"2022","unstructured":"Salimi A.; Schroeder K.M.; Schemionek-Reinders M.; Vieri M.; Maletzke S.; Gezer D.; Masouleh B.K.; Appelmann I.; Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK. BMC Cancer  2022,22(1),735","journal-title":"BMC Cancer"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673352012250414100227","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/241768\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673352012250414100227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T06:04:35Z","timestamp":1772085875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/241768\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298673352012250414100227","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}